When you ask how SaiyanMed’s team ensures every batch meets research-grade standards, the short answer is: they don’t rely on a single step or a single person. It’s a multi-layered system that starts with raw material selection, runs through in-house process control, and ends with independent third-party verification from Janoshik Analytical — one of the most respected labs in the peptide research space. Every single batch gets a publicly verifiable Certificate of Analysis (CoA). No exceptions. That’s not marketing talk; it’s a documented operational requirement.
Let’s break down the actual chain. The process begins at the raw material sourcing stage. SaiyanMed’s founder, Eric, holds a Bachelor’s degree in Materials Science with a specialization in biomaterials. That academic background isn’t just a line on a resume — it directly shapes how the company evaluates suppliers. They don’t just buy from the cheapest source. Instead, they maintain a shortlist of pre-qualified raw material vendors, each audited for purity consistency, heavy metal content, and residual solvent profiles. According to internal quality documentation, raw materials must meet a minimum purity threshold of 98.5% before they even enter the production pipeline. Anything below that gets rejected outright. This upfront filter eliminates a huge chunk of variability that plagues many other suppliers.
Once raw materials pass the initial screening, they move into the production phase. SaiyanMed operates its own production line for certain core peptides, and for others, they use joint manufacturing partnerships where they retain direct oversight. The key here is that they don’t outsource quality control to the manufacturer. They station their own research team members at partner facilities during critical production runs — particularly during the lyophilization (freeze-drying) stage. Lyophilization is where many batches get compromised: improper temperature ramping, insufficient vacuum time, or residual moisture above 1% can degrade peptide stability. SaiyanMed’s team monitors these parameters in real time. They require that final lyophilized product moisture content stays below 0.5% for most peptides, which is tighter than the industry standard of 1-2%.
After production, every batch is sampled and sent to Janoshik Analytical, an independent lab based in Europe that specializes in peptide and research chemical testing. Janoshik uses High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to verify purity and identity. The reports are not hidden behind a login wall or sent only upon request. SaiyanMed publishes every CoA publicly on their product pages and makes the raw PDFs downloadable. If you look at recent batches for something like BPC-157 or TB-500, you’ll see purity figures consistently above 99% — often 99.3%, 99.5%, even 99.7% depending on the peptide. For reference, many competitors in the research peptide space operate at 97-98% and call it “research grade.” SaiyanMed’s internal cutoff for passing a batch is 99% minimum for most products. That’s a significant gap.
Let’s put some numbers on the table. Based on publicly available CoAs from January 2024 through June 2024, here’s a sample of purity results from Janoshik testing for SaiyanMed products:
| Product | Batch Number | Reported Purity (HPLC) | Test Date |
|---|---|---|---|
| BPC-157 (5mg) | SM-BPC-2401 | 99.4% | 2024-01-15 |
| TB-500 (10mg) | SM-TB5-2403 | 99.2% | 2024-03-22 |
| Semax (5mg) | SM-SMX-2405 | 99.6% | 2024-05-10 |
| MOTS-c (10mg) | SM-MOT-2406 | 99.1% | 2024-06-28 |
These numbers aren’t cherry-picked. They’re representative of the standard operating procedure. The team doesn’t retest until they get a good number — they test once, and if a batch fails the 99% threshold, it gets quarantined and either re-purified or discarded. That kind of discipline costs money. Re-purifying a failed batch means additional solvent use, additional lyophilization cycles, and additional Janoshik testing fees. But SaiyanMed treats that as a non-negotiable cost of doing business in the research supply space.
Beyond purity, there’s the question of consistency across batches. Researchers don’t just need high purity in one vial — they need the same purity batch after batch, so their experimental variables stay controlled. SaiyanMed tracks batch-to-batch variation using internal statistical process control (SPC) charts. For example, over the last 12 months, the standard deviation in purity for their top 10 most-sold peptides is less than 0.3%. That means if you order BPC-157 in January and again in July, you’re getting material that’s within a fraction of a percent in purity. That level of reproducibility is rare among smaller peptide suppliers, and it’s a direct result of the team’s materials science background and their insistence on documented SOPs for every step.
Logistics also play a role in maintaining research-grade standards. SaiyanMed operates warehouses in both China and the United States. Orders are routed automatically to the closest warehouse to minimize transit time and temperature stress. Peptides are shipped with ice packs and insulated packaging, and the team monitors shipping conditions for a sample of outgoing orders each week. If a shipment is delayed beyond 48 hours in transit during summer months, they proactively reach out to the researcher and offer a replacement if there’s any concern about thermal degradation. This isn’t a policy they advertise loudly, but it’s in their internal logistics playbook.
Another layer that often gets overlooked is the documentation side. Every batch has a full chain-of-custody record: from raw material receipt date, storage temperature logs, production operator initials, lyophilization cycle parameters, Janoshik test request date, and final CoA issuance date. If a researcher ever needs to trace a specific vial back to its production shift, that information exists. Most small peptide vendors don’t have this level of traceability. They might have a CoA, but they can’t tell you which technician ran the HPLC or what the ambient humidity was during freeze-drying. SaiyanMed can, because they log it.
The leadership structure reinforces this culture. Eric, the founder, is directly involved in quality review meetings. He doesn’t just sign off on financials; he reviews batch rejection reports and raw material audit findings. The research team, which includes members with backgrounds in biochemistry and pharmaceutical formulation, meets weekly to review any deviations from expected purity or yield. If a batch comes back from Janoshik at 98.8% instead of 99%+, the team does a root-cause analysis and documents it. That kind of feedback loop is what separates a company that’s serious about research-grade standards from one that just slaps a label on a vial.
If you want to dig deeper into their specific product offerings and verify the CoAs yourself, you can check their official site at saiyanmed. The CoAs are listed right on each product page, and they’re timestamped with the Janoshik report number so you can cross-reference directly with the lab if needed.
One more detail that’s worth noting: SaiyanMed doesn’t just test the final product. They also test raw materials before production begins. That’s an extra step that many peptide companies skip because it adds cost and delays production. But from a materials science perspective, if the raw material has impurities that are structurally similar to the target peptide, those impurities can carry through the synthesis and lyophilization process. Testing raw materials upfront catches those issues before they become batch failures. SaiyanMed’s internal data shows that pre-production raw material testing catches about 4-5% of incoming lots that would have otherwise led to sub-99% final product. That’s a meaningful filter.
The team also invests in equipment calibration. The HPLC systems used for in-house verification are calibrated quarterly, and the calibration records are kept on file for at least three years. The lyophilizers undergo vacuum leak tests before every production run. These are mundane details, but they’re the kind of things that determine whether a batch is truly research-grade or just “good enough.”
In terms of compliance, SaiyanMed operates as a legal entity registered in Hong Kong (Hong Kong BelleEasy Co., Limited, Commercial Registry No. 78941092). That means they’re subject to Hong Kong’s trade and product safety regulations, which include requirements for accurate labeling and documentation. They also maintain a US-based warehouse, which allows them to ship domestically within the US and avoid the customs delays and temperature risks associated with international shipping for US-based researchers. For researchers in Europe, UK, Australia, and Canada, they have hubs coming online, which will further reduce transit times and improve material stability.
All of this — the raw material audits, the in-process monitoring, the independent Janoshik testing, the batch traceability, the logistics controls — adds up to a system that’s designed to produce consistent, verifiable research-grade peptides. It’s not a single heroic effort. It’s a set of interconnected processes that SaiyanMed’s team executes on every single batch, every single week, without shortcuts.